Abbott Q3 net earnings drop 44% year over year to $920 million
Bitget2026/10/21 11:35- Abbott's third-quarter 2026 net earnings fell 44% year over year to $920 million.
- Net sales rose 15% year over year to $13.01 billion.
- FDA approvals expanded its portfolio with the Libre Duo glucose-ketone sensor and TactiFlex Duo catheter for treating atrial fibrillation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Corporate share buybacks restart, is Wall Street's biggest buyer about to hit the buy button?
The U.S. stock market's corporate buyback window is rapidly reopening as the earnings season blackout period ends. According to data from Goldman Sachs, only 12% of S&P 500 constituents are open for buybacks this week, with another 22% set to exit the blackout. Since October, buyback activity has been about 40% lower than this year's daily average. So far in 2026, buyback authorizations have reached a record $1.305 trillion, and actual buybacks in the first half of the year have increased by 15% compared to the same period last year. With limited supply of new stocks, the supply-demand balance is noticeably shifting in favor of buyback purchases, providing strong technical support for the U.S. stock market.
BUZZ—US Stock Market News—SpaceX, Elevance, Netflix
GBP/USD Price Forecast: Testing resistance at 1.3400 as bullish pressure grows
Crypto prices
More
